CINECA IRIS Institutional Research Information System

PASSIGLIA, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.313
EU - Europa 1.364
AS - Asia 842
SA - Sud America 11
AF - Africa 10
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.549
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.280
IT - Italia 471
CN - Cina 350
IE - Irlanda 338
SG - Singapore 179
SE - Svezia 169
VN - Vietnam 96
FR - Francia 68
GB - Regno Unito 63
UA - Ucraina 58
HK - Hong Kong 51
DE - Germania 41
KR - Corea 38
IN - India 33
PL - Polonia 32
JP - Giappone 29
CA - Canada 23
NL - Olanda 21
ES - Italia 17
FI - Finlandia 12
JO - Giordania 12
DK - Danimarca 9
MX - Messico 9
TW - Taiwan 9
CH - Svizzera 8
HR - Croazia 8
MY - Malesia 8
PK - Pakistan 8
TR - Turchia 8
AU - Australia 6
BA - Bosnia-Erzegovina 6
GR - Grecia 6
RO - Romania 6
RU - Federazione Russa 6
BE - Belgio 5
EG - Egitto 5
IR - Iran 5
PE - Perù 5
CL - Cile 4
NG - Nigeria 4
RS - Serbia 4
SI - Slovenia 4
TH - Thailandia 4
PS - Palestinian Territory 3
SA - Arabia Saudita 3
AP - ???statistics.table.value.countryCode.AP??? 2
AT - Austria 2
CZ - Repubblica Ceca 2
ID - Indonesia 2
ME - Montenegro 2
NO - Norvegia 2
PH - Filippine 2
PT - Portogallo 2
AM - Armenia 1
AR - Argentina 1
BR - Brasile 1
DJ - Gibuti 1
IL - Israele 1
JM - Giamaica 1
MC - Monaco 1
NZ - Nuova Zelanda 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 4.549
Salva come PNG Salva come JPEG
Città #
Dublin 336
Chandler 298
Fairfield 261
Beijing 135
Houston 119
Nyköping 118
Ashburn 115
Singapore 111
Wilmington 111
Seattle 108
Medford 104
Woodbridge 98
Turin 96
Princeton 86
Torino 85
Cambridge 73
Dong Ket 71
Jacksonville 45
Hangzhou 38
Ann Arbor 35
Pisa 34
Warsaw 27
Milan 25
Dearborn 24
Seoul 23
San Diego 19
Hebei 18
Nanjing 18
Amsterdam 17
Central 17
Central District 17
New York 17
Rome 15
Shanghai 15
Los Angeles 14
Norwalk 13
Amman 12
Guangzhou 12
Tokyo 12
Paris 11
Piemonte 11
Redwood City 11
Chengdu 10
London 10
Helsinki 9
Boston 8
Hefei 8
Hong Kong 7
Mumbai 7
Banja Luka 6
Karachi 6
Preveza 6
San Mateo 6
Santa Clara 6
Toronto 6
Brussels 5
Chaponost 5
Chongqing 5
Fuzhou 5
Guiyang 5
Kunming 5
Madrid 5
Munich 5
New Delhi 5
Padova 5
Upper Marlboro 5
Washington 5
Zagreb 5
Abuja 4
Belgrade 4
Brookline 4
Castellaneta 4
Chennai 4
Ciudad Lopez Mateos 4
Duncan 4
Falls Church 4
Genoa 4
Hyderabad 4
Kuala Lumpur 4
Manchester 4
Newcastle upon Tyne 4
Nuremberg 4
Pittsburgh 4
Preston 4
Redmond 4
San Francisco 4
Santiago 4
Stockholm 4
Taipei 4
Tanjong Malim 4
Atlanta 3
Barcelona 3
Bengaluru 3
Bologna 3
Coyoacán 3
Edinburgh 3
Fremont 3
Genay 3
Lappeenranta 3
Luni 3
Totale 3.103
Salva come PNG Salva come JPEG
Nome #
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 260
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 210
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 115
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 106
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 97
Multisciplinary management of patients with liver metastasis from colorectal cancer 90
SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit 89
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 88
Improving lung cancer outcomes through smoking cessation: The women against lung cancer in Europe (WALCE) experience 88
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway 86
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 84
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 81
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation 80
Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure? 76
Nintedanib in NSCLC: Evidence to date and place in therapy 74
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib 73
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era 72
Clinical and molecular features of epidermal growth factor receptor (Egfr) mutation positive non‐small‐cell lung cancer (nsclc) patients treated with tyrosine kinase inhibitors (tkis): Predictive and prognostic role of co‐mutations 72
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature review 71
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 70
Circulating programmed death ligand-1 (cPD-L1) in non-small- cell lung cancer (NSCLC) 70
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 70
Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave 68
Erratum to: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (Scientific Reports, (2018), 8, 1, (13379), 10.1038/s41598-018-30780-4) 65
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design 65
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon? 64
Dealing with NSCLC EGFR mutation testing and treatment: a comprehensive review with an Italian real-world perspective 64
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) 62
Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 Waves 62
Repositioning PARP inhibitors in the treatment of thoracic malignancies 56
Lung Cancer in Italy 55
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 55
Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found… 54
Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle? 53
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 50
KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges 47
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 47
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy 47
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 46
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon 46
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer 45
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 44
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 44
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 43
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 41
Cancer and the microbiome: Potential applications as new tumor biomarker 40
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 40
COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery 40
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer 39
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations 38
Exploring the immune-checkpoint inhibitors' efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: Focus on steroids and autoimmune disease 38
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 37
First-line immune-chemotherapy combination: the right strategy to fight squamous non-small-cell lung cancer?. 37
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 36
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations 35
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 35
Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment 34
Adding chemotherapy to TKI: Can we improve first-line treatment for EGFR-mutated NSCLC patients? 33
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 33
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials 31
The evolving paradigm of precision medicine in lung cancer 30
Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going? 29
Autocrine 17-β-estradiol/estrogen receptor-α loop determines the response to immune-checkpoint inhibitors in non-small cell lung cancer 28
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 28
Entrectinib: A potent new TRK, ROS1, and ALK inhibitor 27
Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All? 27
Real-world retrospective study of KRAS mutations in advanced nonsmall cell lung cancer in the era of immunotherapy 23
A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib 23
Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib? 23
Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression 23
The role of targeted therapy for gastrointestinal tumors 22
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 21
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review 21
The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences 21
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection 20
Winds From the ORIENT: New Data to Inform RATIONAL Choice? 20
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 19
EGFR inhibition in NSCLC: New findings…. and opened questions? 19
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 19
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial 18
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review 18
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 18
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer 18
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 18
Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients-An Italian Single-Center Experience 17
Ramucirumab and its use in gastric cancer treatment 17
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 17
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC 15
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? 15
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 15
Upfront radiation versus EGFR-TKI: Which is the best approach for EGFR-mutated NSCLC patients with brain metastasis? 15
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial 14
The role of germline mutations in thoracic malignancies: between myth and reality 14
Liquid biopsies in lung cancer: The new ambrosia of researchers 14
Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies 13
Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice 13
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups 13
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 12
Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer 12
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun 11
Totale 4.651
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.806
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.806
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020519 0 3 12 57 8 35 53 77 79 81 79 35
2020/2021835 24 46 102 34 79 77 34 59 79 95 50 156
2021/2022957 68 48 50 43 59 39 79 57 42 63 240 169
2022/20231.373 111 115 32 95 101 369 130 89 161 39 81 50
2023/2024751 96 136 35 69 31 47 32 40 13 78 67 107
2024/202574 26 48 0 0 0 0 0 0 0 0 0 0
Totale 4.742